Ai Chip Jitters Hit Mag7 Private Equity And Crypto Stocks Together
On June 26, tech and AI-chip fatigue, private-credit outflow fears, and a Bitcoin pullback hit markets at once, knocking the Magnificent 7, private equity names, MSTR and ON, while GLP-1 biotech leaders like ABBV quietly outperformed.
GLP-1 & Biotech Innovation
What happened?
By June 26, the GLP-1 & Biotech Innovation basket (LLY, ABBV, MRNA, BIIB, VRTX, etc.) had posted a strong, broad-based weekly gain. For this group, it was one of the stronger seven-day stretches in the past year.
Why did it happen?
Two forces came together:
-
Rotation out of overheated AI into defensive growth
As AI and semiconductor leaders corrected in late June, investors looked for the next long-duration growth story that also feels more resilient in a slowdown. GLP-1 obesity/diabetes therapies and large-cap biotech fit that bill: multi‑year demand visibility, strong cash flow, and less direct exposure to capex cycles. -
Solid fundamentals and pipeline depth
Street research continues to lift long-term estimates for obesity drug markets and related cardiometabolic indications. At the same time, big biopharma names like ABBV, LLY, BIIB, VRTX and others back the GLP-1 narrative with diversified pipelines and robust balance sheets, not just a single binary drug bet. -
Macro backdrop favoring quality healthcare
With real yields still elevated and growth leadership looking crowded, quality healthcare and big pharma have re‑emerged as a haven. The group’s combination of dividends, pricing power and structural growth stands out against more cyclical areas.
How did the market react?
- The group’s median seven-day return was close to +8%, a move that ranks near the top of its past-year distribution.
- MRNA surged above +20% over the week, while ABBV, BIIB, VRTX and LLY all posted high single‑digit gains.
- In sharp contrast, the Nasdaq 100 ETF (QQQ) fell more than 4% over the same seven-day span as AI and mega-cap tech pulled back.
In short, capital didn’t leave equities; it moved from AI into high‑quality healthcare.
What can we learn from this move?
- Markets rarely go “risk off” in a vacuum. They often rotate from one growth story to the next. When AI feels stretched, investors hunt for another decade‑long theme that still has room to run.
- Large-cap healthcare can behave like “defensive growth”: less tied to the economic cycle but still capable of compounding earnings at attractive rates.
- Within GLP‑1, the market is rewarding companies with multiple shots on goal and real cash flow more than early‑stage, single‑asset biotech names.
What to watch next
- Key FDA and clinical milestones for GLP‑1 and related cardiometabolic indications. Positive or negative readouts can affect the whole theme at once.
- Drug‑pricing and election headlines in the US. Talk of price controls or reimbursement cuts can quickly knock down valuations.
- Valuation gap vs. AI/tech: if AI leaders correct further and become cheaper again, some of today’s inflows into GLP‑1 and biotech could reverse.
Today’s takeaway
June 26 underscored that money doesn’t disappear; it relocates. As AI took a breather, GLP‑1 and large‑cap biotech quietly became the new destination for growth‑oriented capital. For investors, the lesson is to always track “what’s next” in the market’s growth hierarchy, not just today’s hottest theme.
Private Equity & Asset Management
What happened?
By June 26, the basket of private equity and asset‑management names (ARES, APO, BX, KKR, BLK, GS, MS, SCHW) had sold off hard over the prior week, with a broad, outsized decline compared with their own recent history.
Why did it happen?
The main catalyst was growing concern about redemptions and liquidity pressure in private‑credit and other illiquid vehicles.
On June 26, commentary and research pieces highlighted how higher-for-longer rates and a tougher macro backdrop are pushing some investors to pull money from private funds, particularly those tied to private credit and non‑traded vehicles. Articles singled out Ares, Apollo and similar platforms as especially exposed to this tension between investor outflows and tight withdrawal rules.(simplywall.st)
The story the market told itself was simple:
- Lots of money is locked in private loans and assets.
- If investors want out, managers can’t always sell quickly at good prices.
- That raises the risk of gating, delayed payouts or selling at a discount, all of which hit the perceived value of listed managers.
At the same time, mega‑managers like BLK, as well as GS, MS and SCHW, got dragged in as part of a broader “financials with opaque exposures” worry.
How did the market react?
- Over the week, the group’s median return was around –8%, with several private‑credit‑heavy names down by low double digits.
- ARES, APO, BX and KKR led the slide, reflecting fears about how a stressed credit cycle could bleed into their portfolios.
- The move came even as broader financial indices held up relatively better, showing that this was not just “all banks down” — it was targeted at alternative and private‑markets balance sheets.
What can we learn from this move?
- Illiquidity risk shows up first in the share prices of the managers, not in the funds’ reported NAVs. Those NAVs move slowly, but listed equity reprices expectations instantly.
- High rates plus heavy leverage in private assets are a dangerous combo. Returns looked great when money was free; now, the cost of capital is biting.
- “Blue‑chip” branding doesn’t eliminate funding risk. Even household‑name managers can face pressure if a big chunk of their AUM is in structures where investors are suddenly nervous about getting their money back.
What to watch next
- Redemption and liquidity disclosures from major private‑credit and non‑traded vehicles: any sign of deferred payouts or gates will be a key stress signal.
- Credit spreads and default data in leveraged loans and high yield. A widening in spreads would amplify concerns around private‑credit portfolios.
- Regulatory noise around transparency and leverage in private markets — new rules or disclosure requirements can change the economics of these businesses.
Today’s takeaway
This episode is a reminder that “alternative” does not mean “low risk”. When conditions turn, the market quickly reprices the liquidity and leverage embedded in private‑markets platforms. For investors, it’s crucial to look past headline AUM and study what those assets actually are, how liquid they are, and how they’re financed.
Magnificent 7
What happened?
By June 26, the seven mega‑cap leaders — Apple, Microsoft, Nvidia, Alphabet, Meta, Amazon and Tesla — had all dropped roughly 5–10% over the prior week. For this group, it was one of the more pronounced, synchronized pullbacks in the past year.
Why did it happen?
The backdrop was a broad cool‑down in AI and semiconductor optimism.
On June 26, US market coverage noted that while much of the market held up, AI‑linked tech stocks dragged indexes lower for the week.(apnews.com) Tech and chip names sold off as investors took profits after a long run and digested headlines about potential supply strains and a more volatile capex cycle in AI infrastructure. Reports also highlighted weakness across AI chip makers and broader semiconductors on the day.(www2.stockmarketwatch.com)
The Magnificent 7 sit at the center of that story:
- They are the biggest direct beneficiaries of AI spending (cloud, chips, software).
- They also carry ** outsized index weights**, so any de‑risking tends to start there.
- After years of outperformance, they were trading at rich valuations relative to the rest of the market.
So when questions popped up — “Is AI capex overheating?” “Are memory and supply constraints a problem?” — the easiest trade was to take profits in the biggest winners.
How did the market react?
- The group’s median seven‑day decline was around –7%, noticeably worse than the broader S&P 500.
- Nvidia and other AI‑heavy names led on the downside, but none of the seven escaped — a sign of index‑level, not stock‑specific, de‑risking.
- Behind the scenes, flows showed investors rotating toward more defensive or unloved areas, including healthcare and select value sectors.
What can we learn from this move?
- Concentration cuts both ways. When a handful of stocks drive most of the gains, they also drive most of the pain when sentiment turns.
- A great long‑term story doesn’t protect you from short‑term valuation resets. The business outlook for these firms may still be strong, but prices can overshoot in both directions.
- For index investors, this week is a reminder that owning “the market” often means owning quite a bit of just a few names. Understanding that hidden concentration is critical.
What to watch next
- Upcoming earnings and guidance: how much of the AI narrative is turning into real revenue and profit, and how management teams talk about spending discipline.
- Semiconductor and supply‑chain developments: data on memory, GPU supply, and capex plans will shape how sustainable the AI build‑out looks.
- Rate moves and macro data that could change the discount rate on long‑duration growth cash flows.
Today’s takeaway
The late‑June pullback in the Magnificent 7 is less about any single headline and more about a market catching its breath after a historic run in a tiny group of stocks. For individual investors, the lesson is to separate “great companies” from “great entry prices” — and to be mindful when too much of a portfolio’s fate depends on just a few tickers.
ABBV
What happened?
AbbVie (ABBV) rallied more than 10% over the week into June 26, one of its stronger weekly moves in the past year, even as growth stocks elsewhere were under pressure.
Why did it happen?
ABBV’s move is best seen as company‑specific strength amplified by a favorable sector rotation.
-
Credible earnings and guidance backdrop
Earlier this year, AbbVie raised its full‑year 2026 adjusted EPS guidance, underlining management’s confidence in its post‑Humira portfolio and pipeline.(investors.abbvie.com) In a market suddenly nervous about cyclical earnings risk, that kind of visibility carries a premium. -
Attractive mix of dividend, cash flow and pipeline
AbbVie offers a high, well‑covered dividend backed by strong cash generation, plus exposure to key growth areas like immunology, oncology and metabolic disease. As investors rotate away from more speculative tech, that combination of “income + growth” is appealing. -
Tailwind from GLP‑1 and broader healthcare bid
With GLP‑1 and obesity treatments in the spotlight, large‑cap healthcare names tied to this theme, directly or indirectly, are benefiting from renewed attention. ABBV’s inclusion in GLP‑1/biotech baskets means it is often bought along with sector peers when money flows into the theme.
How did the market react?
- ABBV outperformed both the S&P 500 and its pharma peer group over the week, with a rare double‑digit gain.
- Trading volume picked up as both income‑oriented investors and shorter‑term momentum traders piled in.
- Within GLP‑1 & Biotech Innovation, ABBV ranked among the top performers behind more volatile names like MRNA, but with a much more defensive risk profile.
What can we learn from this move?
- Large, dividend‑paying pharma can behave like “stealth growth stocks” when the pipeline is credible and execution is steady.
- The market is willing to pay up for predictable cash flow plus participation in big secular trends (obesity, immunology, oncology) — especially when high‑beta growth stocks elsewhere feel crowded.
- When a stock sits at the intersection of a hot theme (GLP‑1) and a stable business model, it can outperform both pure defensives and pure growth names.
What to watch next
- Key late‑stage trial results and regulatory decisions across AbbVie’s immunology and oncology franchises.
- US drug‑pricing policy headlines, especially as election rhetoric intensifies.
- Competitive data from rival GLP‑1 and immunology players that could shift market share expectations.
Today’s takeaway
ABBV’s strong week into June 26 is a case study in how a high‑quality compounder can shine when markets get nervous. Rather than chasing the most speculative names in a theme, owning the companies that combine durable earnings with exposure to that theme can sometimes be the more resilient choice.
ON
What happened?
Onsemi (ON) fell more than 20% over the week into June 26, one of its steepest weekly drops in the past year, and far worse than the already weak semiconductor group.
Why did it happen?
The move combined sector‑level selling in chips with stock‑specific demand worries.
-
Broad tech and semiconductor retreat
On June 26, multiple reports pointed to a sell‑off in technology and AI‑linked chip stocks as a key drag on US indexes. Concerns about an overheated AI capex cycle, potential “memory supply crisis” dynamics and profit‑taking after big gains all weighed on the space.(www2.stockmarketwatch.com) -
EV and industrial exposure under scrutiny
ON generates a substantial share of revenue from power semis for electric vehicles and industrial applications. With EV adoption hitting some speed bumps and customers working through excess inventory, the market is quick to assume downside leverage when macro or sector sentiment turns. -
Positioning and leverage in the trade
After a strong 12‑month run, ON had become a popular way to play EV and industrial electrification. That also meant a lot of crowded long positions that could unwind quickly once the tape turned.
How did the market react?
- While the broader semiconductor group fell mid‑single digits on the week, ON dropped more than 20%, placing it among the worst performers in its peer set.
- Options flow showed increased put activity, suggesting investors were not just selling but actively hedging or betting on further downside.
- The stock broke through recent support levels, which likely triggered additional technical selling from rules‑based strategies.
What can we learn from this move?
- Even within semis, end‑market mix matters. Names tied heavily to EVs and cyclical industrial demand can move very differently from data‑center‑focused chipmakers.
- When a theme (EV + electrification) is popular, the stocks attached to it can become crowded — which makes reversals sharper when sentiment cools.
- A large weekly drop is not automatically a bargain; investors need to distinguish between temporary de‑risking and a genuine change in the demand outlook.
What to watch next
- Next earnings report and guidance from ON, especially commentary on EV and industrial order trends and customer inventories.
- Production and pricing news from major EV makers that could ripple through ON’s order book.
- Signals from the broader chip complex: if AI‑related semis stabilize while ON continues to lag, that may point to more stock‑specific issues.
Today’s takeaway
ON’s steep slide into June 26 shows how quickly sentiment can swing on a stock that sits at the intersection of cyclical demand and a crowded long theme. For investors, it’s a reminder to look beyond the sector label and understand exactly which end markets your chip company really depends on.
MSTR
What happened?
MicroStrategy (now often branded simply as Strategy, ticker MSTR) dropped more than 30% over the week into June 26 and nearly 50% over the past month, while Bitcoin slid below $60,000 and briefly toward $58,000.(thecurrencyanalytics.com)
Why did it happen?
Three pressure points lined up at once:
-
Bitcoin’s late‑June selloff
Weak risk sentiment and a wave of derivatives liquidations after macro data releases pushed Bitcoin under $60k, sparking forced selling in leveraged long positions. That set the backdrop for any Bitcoin‑linked equity to struggle.(investing.com) -
Concerns around Strategy’s leverage and STRC
Strategy has financed its massive Bitcoin hoard with a mix of convertible debt and a perpetual preferred stock called STRC. As Bitcoin fell, STRC itself traded down to a steep discount to par, raising questions about investor confidence in the structure and the sustainability of its double‑digit yield.(theblock.co) That magnified worries that the firm is, in effect, a highly levered Bitcoin vehicle. -
Options and sentiment spirals
Market commentary pointed to heavy put activity around the June 25–26 sessions, with large downside bets in MSTR hitting the tape right at the open and accelerating the drop.(guygentile.com) As the stock fell, more technical and risk‑managed sellers stepped in, reinforcing the slide.
How did the market react?
- MSTR’s decline was far steeper than Bitcoin’s: roughly 3–4x the drawdown over the week, consistent with its history of behaving like a leveraged BTC proxy.(beincrypto.com)
- Crypto‑linked equities broadly traded lower, but MSTR stood out as the focal point of market anxiety about debt‑funded Bitcoin accumulation.
- On retail forums, debate raged over whether MSTR had become “cheaper than the Bitcoin it owns” and thus a deep‑value play, or whether structural risks justified a persistent discount.(beincrypto.com)
What can we learn from this move?
- Owning MSTR is not the same as owning spot Bitcoin. You’re taking exposure to BTC plus the company’s leverage, capital structure, and management decisions.
- Complex funding tools like convertibles and high‑yield preferreds can supercharge returns in a bull market — but they also magnify downside in a drawdown and can spark reflexive fear when prices fall.
- Market narratives matter: once a stock becomes a symbol of a theme (here, “leveraged BTC bet”), flows and sentiment can dominate near‑term price action regardless of fundamentals.
What to watch next
- Bitcoin’s path and volatility: further declines into the mid‑$50k area would keep pressure on MSTR and STRC.
- Updates on Strategy’s balance sheet: any moves to refinance debt, adjust STRC terms or change the Bitcoin accumulation strategy will be critical.
- Regulatory and accounting developments affecting corporate Bitcoin holdings, which could alter how investors value MSTR relative to its coins.
Today’s takeaway
MSTR’s crash into June 26 is a live demonstration of how thematic flag‑bearers can behave like leveraged options on their underlying asset. For investors tempted by “cheap exposure” via such proxies, the key is to understand not just the asset you’re indirectly buying, but also the financing structure and downside mechanics that come with it.
This content is for informational purposes only and does not constitute a recommendation to invest in any specific security or asset.